Ola Winqvist

CEO and Co-founder +46 70 542 79 39

CEO since 2018, former CSO in the company, born 1962. Holding per 2021-06-30 Number of shares: 117,094 via related parties. Number of warrants: 7,500 TO2 via related parties.

Ola Winqvist has more than 30 years of experience in immunological research and is a professor of cellular immunotherapy and chief physician in clinical immunology. He was previously chairman of the Swedish Immunology Association and is now chairman of the Swedish Medical Association's research delegation. The Cancer Foundation and the Swedish Research Council have continuously supported Olas research since 1999. He has also received various competitive grants from the European Union and the Swedish Agency for Innovation Systems for the Development of Immunological Therapy. Ola Winqvist is a specialist and Chief Physician in Clinical Immunology and has a doctorate from Uppsala University in Sweden. He has more than 30 patents and has started several spin-off companies. In 2013, his research was awarded the Athena Prize.

Other assignments: Chairman of the Delegation for research at the Swedish Medical Association and ImmunoWise AB. Board member of, among others, TLA Targeted Immunotherapies AB.


Jonas Winqvist


COO/CFO since 2021, born 1969. Holding per 2021-06-30 Number of shares: 117,094 via related parties.

Hired as a consultant from Implement Consulting Group. Previous experience as an accountant and management consultant with a focus on organizational and business development.


Johan Sjödahl


CSO since 2021, former Head R&D in the company, born 1972. Holding per 2021-06-30 Number of shares: 7,500.

Johan Sjödahl has a MSc in Chemical engineering and a PhD in Analytical Chemistry from the Royal Institute of Technology in Stockholm. He has been 25 years in the Life Science field and has experiences from pharmaceutical and medtech product development from BioArctic, Bactiguard and Orkla.


Sven Rohmann


CCO since 2021, born 1962 in Germany.

Dr. Rohmann’s unique blend of scientific, pharma/biotech and venture knowledge, an extensive network of contacts among health care providers as well as academic and government research administrators, a thorough knowledge of global research & development as well as EMA/FDA regulatory policies, and a significant experience in M&A and partnering makes him one of the leading experts in innovation management, value building & capturing.

He spent 10 years at Merck Serono, which provided him with a strong foothold in the pharmaceutical industry. His career exposed him to pre-clinical, clinical development as well as marketing, business and corporate development. During his tenure at Merck he headed the establishment of Merck Oncology and built a complete clinical asset portfolio including the successful licensing of Erbitux (now a >$3bn annual sales product).

Dr. Rohmann left Merck to become the Managing Partner of Nextech Venture in Switzerland. With Nextech Venture he raised two funds and returned up to 8x multiples to the investors. After this, Dr. Rohmann was responsible as Venture Capital Fund Manager for a Novartis Pharma AG – MPM Capital fund ($0.55bn), and gained board experience at many SME’s in Europe, US and Canada.

From 2010 until 2014 he was the General Manager Europe for Burrill& Co., a Healthcare Venture Fund with more than $1.5bn under management. One highlight of the fund was the Pharmasset asset, which was sold to Gilead for $11bn. In addition, Dr. Rohmann served as the founding CEO of Ganymed Pharmaceuticals AG, which was sold to Astellas in 2016 for up to $1.4bn. The founder team was the same as for Biontech, which is since 2019 listed at the US NASDAQ.

In 2016 he founded Suenos Advisors Establishment in Liechtenstein which since then serves as his Management & Investment vehicle. From 2016 onwards he served on the board and/or as interim CEO of the public companies Helix Pharmaceutical Corp., Oasmia Pharmaceutical AB and Immunicum AB. Furthermore, he supports the Stockholm-based oncology start-up NEOGAP AB.

Dr. Rohmann actually advises Oryx Alpha GmbH, a translational medicine company working on the premium assets from the German Cancer Center (DKFZ),  as well as the Center for Molecular Medicine (CMM) of Karolinska Institute, Stockholm, Sweden.

Dr. Rohmann received his MD from the University of Mainz, Germany, and his PhD from the Erasmus University, Rotterdam, Netherlands.

Board of Directors


Anders Milton

Chairman of the board

Chairman of the Board since 2016, born 1947. Holdings per 2021-06-30 Number of shares: 209,482 and 1,020,215 via related parties. Number of warrants: 29,926 TO2 and 16,092 TO2 via related parties.

Anders Milton has a PhD from Uppsala University. Milton has held several different leading positions in both the private and public sector. Including the government's national psychiatric coordinator, chairman of the Swedish Academics' Central Organization (SACO), the Swedish Red Cross and the Swedish Medical Association where he later was CEO. Milton was also a member of the disaster commission that was appointed after the tsunami disaster in 2004. He has led investigations into – among other things – Sweden’s HIV and AIDS policy, organ donation and transplantation, and what society can do to reduce the number of abortions in Sweden.

Other assignments: Chairman of Vironova AB (publ), board member of HumaNova Utbildning AB, and more.

Independent in relation to ISR and the company management and the company's major shareholders.


Gunnar Jardelöv

Co-Founder and Member of the Board

Board member since 2016, born 1947. Holding per 2021-06-30 Number of shares: 247,775 and 232,963 via related parties. Number of warrants: 21,178 TO2 via related parties.

Gunnar Jardelöv has a degree in economics and a Master of Business Administration from the School of Business, Economics and Law at the University of Gothenburg. Jardelöv has over 50 years of experience from having worked in Sweden and abroad as CEO and member or chairman of several companies. He has developed and led a number of companies that were later sold in industries such as shipping, forwarding, oil storage, real estate, streaming services and IT. Jardelöv is now active as an investor and business angel, as well as, among other things, the assignments listed below.

Other assignments: Chairman of Seamless Distribution Systems AB and Derma Cure Sverige AB.

Independent in relation to ISR and the company management. Not independent in relation to the company's major shareholders.


Hans Glise

Member of the board

Board member since 2017, born 1952. Holding per 2021-06-30 Number of shares: 156,594. No warrants.

Hans Glise has an MD and PhD from the University of Gothenburg. He is a professor and expert in pharmaceutical product development and innovation-driven collaborative research. Prior to founding ITH, Hans was Vice President and Senior Vice President at AstraZeneca, NovoNordisk and UCB.

Other assignments: Chairman of the Board of TLA Targeted Immunotherapies AB and ITH Immune Therapy Holdings AB, among others.

Independent in relation to ISR and the company management as well as the company's major shareholders.